SCD-HeFT update
This article was originally published in The Gray Sheet
Executive Summary
CMS will "undertake a complete review of the available literature" on prophylactic implantation of ICDs in patients with poor ventricular function, including SCD-HeFT, DINAMIT, DEFINITE and COMPANION clinical trials, CMS announces March 30. The agency also will assess evidence pertaining to selection of appropriate defibrillators for specific patient populations. The review responds to 1Medtronic's March 18 request that CMS amend its ICD coverage policy to include all patients with at least one year of remaining life expectancy, documented congestive heart failure for greater than 3 months and left-ventricular function of less than 35% - the indication evaluated in the SCD-HeFT trial. Following release of CMS' ICD coverage policy in 2003, the agency agreed to revisit its coverage criteria once SCD-HeFT results were unveiled (2"The Gray Sheet" March 15, 2003, p. 3)...
You may also be interested in...
CMS Welcomes SCD-HeFT Data, Awaits COMPANION Study For ICD Review
CMS plans to integrate Guidant's COMPANION study findings with recently released data from the SCD-HeFT trial to make a decision on whether to redefine the patient population eligible for ICD coverage
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.